DJ bonyf NV Showcases Innovative Product Portfolio at ExpoPharm 2025 in Düsseldorf
bonyf NV / Key word(s): Conference/Corporate Action bonyf NV Showcases Innovative Product Portfolio at ExpoPharm 2025 in Düsseldorf 15-Sep-2025 / 17:28 CET/CEST =---------------------------------------------------------------------------------------------------------------------- bonyf NV Showcases Innovative Product Portfolio at ExpoPharm 2025 in Düsseldorf Knokke-Heist (Belgium), 15 September 2025, 6:00 a.m.; bonyf NV (Ticker: MLBON), the next-generation oral comfort expert, listed on Euronext Paris, announces its participation at ExpoPharm 2025, one of Europe's largest pharmaceutical trade fairs, held in Düsseldorf from 16 to 18 September 2025. At this prestigious event, bonyf will present its latest portfolio of groundbreaking innovations, including: -- PerioCream: a patented solution for periodontitis patients, designed as an effective adjunct to scaling and root planing. -- GumFix: an advanced gum care treatment that helps reduce bleeding and discomfort while protecting sensitive gums. -- NailFix: an innovative formula targeting damaged nails, restoring appearance and strength. -- EfferWhite: an advanced effervescent whitening solution designed for safe and effective teeth brightening. The ExpoPharm Platform for Innovation ExpoPharm is Europe's leading trade fair for the pharmacy sector, bringing together pharmacists, healthcare professionals, and industry leaders to discuss the latest trends and innovations in healthcare. The Düsseldorf event provides bonyf with a powerful stage to highlight its clinically validated and patented solutions that address urgent needs in oral, dental, and personal care. Jean-Pierre Bogaert, CEO of bonyf, said: "We are delighted to participate at ExpoPharm 2025, presenting our latest products to healthcare professionals and partners. Our focus on innovation and clinical efficacy enables us to bring real solutions that improve patients' daily lives and expand opportunities for our commercial partners." Visit bonyf in Düsseldorf at ExpoPharm Hall 1 E-20 to discover the latest innovations of the bonyf R&D department at firsthand. For more information or to schedule a meeting at ExpoPharm 2025, please contact: investor@bonyf.com. bonyf's strengths -- Products with patented formulations -- Produced in Switzerland compliant with stringent international quality regulations -- Proven clinical efficacy -- Commercial presence in 37 countries -- Prospects for solid growth and rapid profitability -- A fast-growing oral and dental care market About bonyf bonyf is a European innovator in oral and dermatological care, developing clinically validated solutions for dental professionals, pharmacies, and consumers. Listed on Euronext Paris (MLBON), bonyf is headquartered in Knokke, Belgium, and operates with a growing global presence across Europe, Asia, and the Americas. For more information, visit bonyf.com or contact investor@bonyf.com. bonyf Jean-Pierre Bogaert investor@bonyf.com
----------------------------------------------------------------------------------------------------------------------- Attachment
File: EN_PR_bonyf NV Showcases Innovative Product Portfolio at ExpoPharm 2025 in Düsseldorf
-----------------------------------------------------------------------------------------------------------------------
Dissemination of a Financial Wire News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
-----------------------------------------------------------------------------------------------------------------------
Language: English
Issuer: bonyf NV
Kalvekeetdijk 179, box 105
8300 Knokke-Heist
Belgium
Phone: +41 79 412 42 79
E-mail: president@bonyf.com
Internet: www.bonyf.com
ISIN: BE6333353298
EQS News ID: 2197724
End of Announcement - EQS News Service
=------------------------------------------------------------------------------------
2197724 15-Sep-2025 CET/CEST
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2197724&application_name=news&site_id=dow_jones%7e%7e%7ebed8b539-0373-42bd-8d0e-f3efeec9bbed
(END) Dow Jones Newswires
September 15, 2025 11:29 ET (15:29 GMT)
